Profile
| Metric | Value |
|---|---|
| Full Name | Avidity Biosciences, Inc. |
| Ticker | NASDAQ: RNA |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | aviditybiosciences.com |
| Employees | 391 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $72.07 | |
| Price, 1D Change | -0.04% | |
| Market Cap | $11B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.08 | |
| Revenue | $11M | |
| Revenue, 1Y Change | +13.99% | |
| EPS | -$2.89 | |
| EPS, 1Y Change | +0.62% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$2.89 | |
| EPS Estimate | -$4.49 | |
| EPS Est. Change | -55.41% | |
| Revenue | $10.90M | |
| Revenue Estimate | $18.36M | |
| Revenue Est. Change | +68.48% | |
| Current Price | $72.07 | |
| Price Target | - | $72.00 |
| Price Tgt. Change | - | -0.10% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$2.74 | -$2.91 | -6.08% | |
| -$2.86 | -$2.89 | -1.09% | |
| -$4.49 | N/A | -55.41% | |
| -$4.89 | N/A | -69.30% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| $9.56M | $9.56M | 0.00% | |
| $9.75M | $10.90M | +11.76% | |
| $18.36M | N/A | +68.48% | |
| $19.34M | N/A | +77.46% |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +136.30% | |
| Price, 3Y | +271.49% | |
| Market Cap, 1Y | +196.96% | |
| Market Cap, 3Y | +702.31% | |
| Revenue, 1Y | +13.99% | |
| Revenue, 3Y | +16.85% | |
| EPS, 1Y | +0.62% | |
| EPS, 3Y | -1.40% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $72.07 | |
| SMA 200 | $44.83 | |
| SMA 200 vs Price | -37.80% | |
| SMA 50 | $70.26 | |
| SMA 50 vs Price | -2.51% | |
| Beta | 1.08 | |
| ATR | $0.37 | |
| 14-Day RSI | 70.59 | |
| 10-Day Volatility | 1.96% | |
| 1-Year Volatility | 76.40% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $10.90M | |
| EPS | -$2.89 | |
| Gross Profit | $8.12M | |
| Gross Margin | 74.53% | |
| Operating Profit | -$378.94M | |
| Operating Margin | -3,477.43% | |
| Net Income | -$322.30M | |
| Net Margin | -2,957.71% | |
| EBITDA | -$376.16M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.00 | |
| Current Ratio | 15.73 | |
| Quick Ratio | 15.73 | |
| - | ||
| F-Score | 1 | |
| Altman Z-Score | 46.41 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | 520.38 | |
| PB Ratio | 5.76 | |
| EV/EBITDA | -14.83 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $1.42B | |
| Cash & Equivalents | $219.87M | |
| Total Assets | $1.56B | |
| Current Assets | $1.54B | |
| Total Liabilities | $138.94M | |
| Current Liabilities | $98.02M | |
| Total Debt | $6.80M | |
| Short Term Debt | $3.84M | |
| Accounts Payable | $8.46M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $389.83M | |
| Operating Expenses | $389.83M | |
| Cost Of Goods Sold | $2.78M | |
| SG&A | $86.24M | |
| D&A | $2.78M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$300.87M | |
| CFI | -$854.20M | |
| CFF | $1.19B | |
| Capex | $7.07M | |
| Free Cash Flow | -$307.94M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Chardan Capital | → | |
| TD Cowen | → | |
| RBC Capital | → | |
| Chardan Capital | → | |
| Raymond James | → | |
| Needham | → | |
| Leerink Partners | → | |
| HC Wainwright & Co. | → | |
| Citigroup | → | |
| Bernstein | → |
Analyst sentiment
Institutional ownership
Screeners with RNA
Data Sources & References
- RNA Official Website www.aviditybiosciences.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1599901/000159990125000210/0001599901-25-000210-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1599901/000159990125000059/0001599901-25-000059-index.htm
- RNA Profile on Yahoo Finance finance.yahoo.com/quote/RNA
- RNA Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/rna
FAQ
What is the ticker symbol for Avidity Biosciences, Inc.?
The ticker symbol for Avidity Biosciences, Inc. is NASDAQ:RNA
Does Avidity Biosciences, Inc. pay dividends?
No, Avidity Biosciences, Inc. does not pay dividends
What sector is Avidity Biosciences, Inc. in?
Avidity Biosciences, Inc. is in the Healthcare sector
What industry is Avidity Biosciences, Inc. in?
Avidity Biosciences, Inc. is in the Biotechnology industry
What country is Avidity Biosciences, Inc. based in?
Avidity Biosciences, Inc. is headquartered in United States
When did Avidity Biosciences, Inc. go public?
Avidity Biosciences, Inc. initial public offering (IPO) was on June 12, 2020
Is Avidity Biosciences, Inc. in the S&P 500?
No, Avidity Biosciences, Inc. is not included in the S&P 500 index
Is Avidity Biosciences, Inc. in the NASDAQ 100?
No, Avidity Biosciences, Inc. is not included in the NASDAQ 100 index
Is Avidity Biosciences, Inc. in the Dow Jones?
No, Avidity Biosciences, Inc. is not included in the Dow Jones index
When was Avidity Biosciences, Inc. last earnings report?
Avidity Biosciences, Inc.'s most recent earnings report was on November 10, 2025
When does Avidity Biosciences, Inc. report earnings?
The next expected earnings date for Avidity Biosciences, Inc. is March 2, 2026